Bullfrog AI Collaboration is ‘First Step Towards Personalized Medicine in Psychiatry’; Shares Soar 30%
Bullfrog AI (Nasdaq: BRFG) shares are up more than 32% in morning trading on Wednesday after the company announced a collaboration with the Lieber Institute for Brain Development (LIBD)
that could revolutionize our understanding and treatment of psychiatric disorders. The company’s shares soared more than 30% in morning trading on Wednesday.
The market opportunity for new treatments in psychiatric disorders is significant and underserved particularly with increasing global awareness and demand for mental health solutions.
Bullfrog specializes in technology-enabled drug development using AI and machine learning to enable the successful development of pharmaceuticals and biologics.
Commenting on the partnership, Vin Singh, CEO of BullFrog AI, said, “This collaboration marks a pivotal moment in psychiatric research. By employing our bfLEAP™ platform on LIBD’s unrivaled brain data, we’ve gained invaluable ground into unraveling the biological underpinnings of psychiatric disorders. These preliminary findings have the potential to not only deepen our understanding but also pave the way for developing more targeted and effective treatments that set the stage for us to seek out revenue-generating strategic partnerships with pharmaceutical companies.”
The early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.
Daniel R. Weinberger, M.D., Director and CEO of LIBD, added, “Our collaboration with BullFrog AI has enabled us to apply cutting-edge AI technologies to our extensive brain data. The preliminary results are provocative and offer novel insights at the gene level that may only be discoverable using these novel AI technologies, offering a new lens through which we can view and potentially treat brain disorders. This is an important first step towards personalized medicine in psychiatry.”
The agreement between the organizations grants BullFrog AI exclusive access to LIBD’s brain data, with the potential to commercialize products or services derived from the collaboration.
About BullFrog AI
BullFrog AI is a technology-enabled drug development company using Artificial Intelligence and machine learning to enable the successful development of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform to create and analyze networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.
